1-20 of 74
Stefan Knop
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Clinical Trials & Observations
Ola Landgren, Thomas J. Prior, Tara Masterson, Christoph Heuck, Orlando F. Bueno, Ajeeta B. Dash, Hermann Einsele, Hartmut Goldschmidt, Stefan Knop, Cong Li, Ulf-Henrik Mellqvist, Ian McFadden, Corina Oprea, Jeremy A. Ross, Mihaela Talpes, Jay R. Hydren, Jennifer M. Ahlstrom, Dickran Kazandjian, Niels Weinhold, Rick Zhang, Maryalice Stetler-Stevenson, Gerald Marti, Sean M. Devlin
Journal: Blood
Blood (2024) 144 (4): 359–367.
https://doi.org/10.1182/blood.2024024371
Published: 2024
Includes: Supplemental data
Journal Articles

Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma

Christian Straka, Kerstin Schaefer-Eckart, Bernd Hertenstein, Florian Bassermann, Hans Salwender, Christian Langer, Jan Krönke, Miriam Kull, Georgia Schilling, Aneta Schieferdecker, Monika Engelhardt, Stefan Knop, Julia Reusch, Wolf Roesler, Bernd Metzner, Holger Hebart, Albrecht Reichle, Matthias Grube, Norbert Frickhofen, Christian Gerecke, Stephan Fuhrmann, Wolfram Jung, Martin Gramatzki, Thomas Decker, Tobias Dechow, Jochen Greiner, Tim H. Brümmendorf, Juliana Ababei, Ivana von Metzler, Ralph Naumann, Elisabeth Fritz, Marcus Hentrich, Peter Bojko, Thomas Kubin, Christian Schmidt, Martin Kaufmann, Burkhard Schmidt, Axel Hinke, Hermann Einsele
Journal: Blood
Blood (2022) 140 (Supplement 1): 287–288.
https://doi.org/10.1182/blood-2022-159357
Published: 2022
Journal Articles

Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

Heinz Ludwig, Thomas Melchardt, Siegfried Sormann, Niklas Zojer, Johannes Andel, Bernd L. Hartmann, Christoph Tinchon, Eberhard Gunsilius, Klaus Podar, Alexander Egle, Wolfgang Willenbacher, Ewald Wöll, Martin Schreder, Reinhard Ruckser, Boris Bozic, Maria-Theresa Krauth, Andreas Petzer, Clemens A. Schmitt, Sigrid Machherndl-Spandl, Hermine Agis, Michael Fillitz, Song-Yau Wang, Stefan Knop, Sarah Kainz, Bruno Paiva, Richard Greil
Journal: Blood
Blood (2022) 140 (Supplement 1): 10185–10188.
https://doi.org/10.1182/blood-2022-162336
Published: 2022
Journal Articles

Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study

Maria-Victoria Mateos, Jesús San-Miguel, Michele Cavo, Joan Bladé Creixenti, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lucio, Zsolt Nagy, Ludek Pour, Sebastian Grosicki, Andre H Crepaldi, Anna Marina Liberati, Philip Campbell, Tatiana Shelekhova, Sung-Soo Yoon, Genadi Iosava, Tomoaki Fujisaki, Mamta Garg, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Meletios A. Dimopoulos
Journal: Blood
Blood (2022) 140 (Supplement 1): 10157–10159.
https://doi.org/10.1182/blood-2022-163347
Published: 2022
Journal Articles

Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial

Sagar Lonial, Rakesh Popat, Cyrille Hulin, Sundar Jagannath, Albert Oriol, Paul G. Richardson, Thierry Facon, Katja Weisel, Jeremy T. Larsen, Monique C. Minnema, Al-Ola Abdallah, Ashraf Z. Badros, Stefan Knop, Edward A. Stadtmauer, Min Chen, Tuong Vi Nguyen, Alpesh Amin, Elisabeth Kueenburg, Teresa Peluso, Niels W.C.J. van de Donk
Journal: Blood
Blood (2021) 138 (Supplement 1): 162.
https://doi.org/10.1182/blood-2021-147704
Published: 2021
Journal Articles

Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)

Irene Manrique, Richard Greil, Johannes Andel, Siegfried Sormann, Bernd L. Hartmann, Klaus Podar, Alexander Egle, Andreas Petzer, Niklas Zojer, Eberhard Gunsilius, Reinhard Ruckser, Boris Bozic, Clemens A. Schmitt, Sigrid Machherndl-Spandl, Hermine Agis, Martin Schreder, Song-Yau Wang, Wolfgang Willenbacher, Maria-Theresa Krauth, Christoph Tinchon, Michael Fillitz, Thomas Melchardt, Stefan Knop, Bruno Paiva, Heinz Ludwig
Journal: Blood
Blood (2021) 138 (Supplement 1): 1669.
https://doi.org/10.1182/blood-2021-150311
Published: 2021
Journal Articles

Patterns of Renal Recovery and Toxicity with Novel Agent-Based Induction Triplets in Newly Diagnosed Multiple Myeloma - an Analysis of Two Prospective Studies By the German DSMM Myeloma Study Group

Friederike Bachmann, MD, Swantje Held, Monika Engelhardt, MD, Christian Langer, MD, Denise Wolleschak, Janik Fleissner, Lars-Olof Mügge, MD, Heinz Duerk, MD PhD, Martin Schreder, MD, Kerstin Schaefer-Eckart, MD, Igor-Wolfgang Blau, MD PhD, Martin Gramatzki, MD, Peter Liebisch, MD, Albrecht Reichle, MD, Ivana Metzler, MD, Florian Bassermann, MD PhD, Bernd Metzner, MD PhD, Christoph Röllig, MD MSC, Bernd Hertenstein, Tobias Dechow, Wolfram Jung, MD, Helmut Ostermann, MD, Holger Hebart, Georg Maschmeyer, MD, Hans Jürgen Salwender, MD, Marie von Lilienfeld-Toal, MD, Kai-Uwe Eckardt, MD, Christian Straka, MD PhD, Hermann Einsele, MD, Stefan Knop
Journal: Blood
Blood (2019) 134 (Supplement_1): 1840.
https://doi.org/10.1182/blood-2019-125235
Published: 2019
Journal Articles

The MP0250-CP201 Mirror Study: A Phase 2 Study Update of MP0250 Plus Bortezomib and Dexamethasone in Relapse/Refractory Multiple Myeloma (RRMM) Patients Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs

Norbert Grząśko, MD PhD, Stefan Knop, Hartmut Goldschmidt, MD, Marc S Raab, MD PhD, Jan Dürig, Sara Bringhen, Mattia D'Agostino, MD, Barbara Gamberi, Elena Rivolti, MD, Angelo Vacca, MD PhD, Roberto Ria, MD, Artur Jurczyszyn, MD, Jorge Castellano Acosta, MD, Doris Lang, Guy Lemaillet, PhD, Bansod Sudhir, MD, Monika Szarejko, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1899.
https://doi.org/10.1182/blood-2019-129827
Published: 2019
Journal Articles

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone

Maria-Victoria Mateos, Michele Cavo, Joan Bladé, MD PhD, Meletios A. Dimopoulos, MD, Kenshi Suzuki, MD PhD, Andrzej Jakubowiak, MD PhD, Stefan Knop, Chantal Doyen, MD, Paulo Lucio, MD PhD, Zsolt Nagy, MD PhD, Ludek Pour, MD, Mark Cook, MBChB,PhD, Sebastian Grosicki, MD PhD, Andre H Crepaldi, MD, Anna Marina Liberati, Philip Campbell, MBBS, FRACP, FRCPA, Tatiana Shelekhova, Sung-Soo Yoon, MD PhD, Genadi Iosava, MD, Tomoaki Fujisaki, MD PhD, Mamta Garg, MD FRCP, FRCPath, Maria Krevvata, PhD, Jianping Wang, Anupa Kudva, MD, Jon Ukropec, PhD, Susan Wroblewski, PhD, Rachel Kobos, MD, Jesús San-Miguel
Journal: Blood
Blood (2019) 134 (Supplement_1): 859.
https://doi.org/10.1182/blood-2019-123401
Published: 2019
Journal Articles

One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone

Meletios A Dimopoulos, MD, Maria-Victoria Mateos, MD PhD, Michele Cavo, MD, Kenshi Suzuki, MD PhD, Andrzej Jakubowiak, MD PhD, Stefan Knop, Chantal Doyen, MD, Paulo Lucio, Zsolt Nagy, MD PhD, Polina Kaplan, Ludek Pour, MD, Mark Cook, MBChB,PhD, Sebastian Grosicki, MD PhD, Andre H Crepaldi, MD, Anna Marina Liberati, MD, Philip Campbell, MBBS, FRACP, FRCPA, Tatiana Shelekhova, Sung-Soo Yoon, MD PhD, Genadi Iosava, MD, Tomoaki Fujisaki, MD PhD, Mamta Garg, Christopher Chiu, PhD, Jianping Wang, Anupa Kudva, Rachel Kobos, MD, Susan Wroblewski, PhD, Ming Qi, MD PhD, Jesus F San-Miguel, MD PhD, Joan Bladé, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 156.
https://doi.org/10.1182/blood-2018-156
Published: 2018
Journal Articles

Ixazomib in Combination with Thalidomide and Dexamethasone for Induction and Ixazomib Maintenance Therapy Overcomes High-Risk Cytogenetics (but not of 1q21 Gain) in Relapsed/Refractory Multiple Myeloma — AGMT_MM1

Heinz Ludwig, MD, Wolfram Pönisch, MD, Stefan Knop, Martin Schreder, MD, Daniel Lechner, MD, Roman Hajek, MD PhD, Eberhard Gunsilius, MD, Karl Jochen Krenosz, MD, Andreas Petzer, MD, Katja Weisel, MD, Hermann Einsele, MD PhD, Richard Greil, MD, Niklas Zojer, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3275.
https://doi.org/10.1182/blood-2018-99-118061
Published: 2018
Journal Articles

Induction with Bortezomib Melphalan and Prednisolon (VMP) Is Associated with Unexpectedly High Discontinuation Rate in Elderly Multiple Myeloma Patients: First Analysis of the German Maintenance (GERMAIN) Trial

Annamaria Brioli, MD, Kirsi Manz, Mathias Hänel, MD, Markus Pfirrmann, PhD, Andreas Christoph Schwarzer, MD, Marie von Lilienfeld-Toal, MD, Gabriele Prange-Krex, Christian Fabisch, PhD, Stefan Knop, Thomas Illmer, MD, Beate Krammer-Steiner, Andreas Hochhaus, MD, Lars-Olof Mügge, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2016.
https://doi.org/10.1182/blood-2018-99-115964
Published: 2018
Journal Articles

Lenalidomide, Adriamycin and Dexamethasone (RAD) Versus Bortezomib, Lenalidomide and Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) - Post-Induction Response and MRD Results By Flow Cytometry and NGS from a Phase 3 Randomized Controlled Clinical Trial (RCT)

Thomas Stübig, MD, Christian Langer, MD, Monika Engelhardt, MD, Lars-Olof Mügge, MD, Florian Bassermann, MD PhD, Martin Schreder, MD, Kerstin Schäfer-Eckart, MD, Igor Wolfgang Blau, Denise Wolleschak, Albrecht Reichle, MD, Ivana Metzler, MD, Bernd Metzner, MDPhD, Christoph Rollig, MD MSC, Bernd Hertenstein, MD, Heinz Dürk, Harald Biersack, MD, Helge Menzel, MD, Tobias Dechow, Jan Schleicher, Martin Gramatzki, MD, Tim H. Brümmendorf, MD, Stephan Fuhrmann, Max Bittrich, MD, Franziska Appelt, Martina Müller, Jan Krönke, MD, Julia Reusch, Christian Schmidt, MD, Monika Brüggemann, MD, Swantje Held, Stefan Knop, Hermann Einsele, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1979.
https://doi.org/10.1182/blood-2018-99-116067
Published: 2018
Journal Articles

MP0250 Combined with Bortezomib and Dexamethasone in Multiple Myeloma Patients Previoulsy Exposed to Proteasome Inhibitors and Immunomodulatory Drugs

Stefan Knop, Hartmut Goldschmidt, MD, Marc S Raab, MD PhD, Monika Szarejko, Artur Jurczyszyn, MD, Jan Dürig, Sara Bringhen, Barbara Gamberi, MD, Angelo Vacca, Jorge Castellano Acosta, MD, Guy Lemaillet, PhD, Cedric Cortijo, PhD, Bansod Sudhir, Norbert Grząśko, MDPhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1980.
https://doi.org/10.1182/blood-2018-99-112859
Published: 2018
Journal Articles

Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)

Maria-Victoria Mateos, Meletios A. Dimopoulos, Michele Cavo, MD, Kenshi Suzuki, Andrzej J. Jakubowiak, MD, Stefan Knop, MD, Chantal Doyen, MD, Paulo Lucio, Zsolt Nagy, MD PhD, Polina Kaplan, Ludek Pour, Doc,MD PhD, Mark Cook, MBChB,PhD, Sebastian Grosicki, MD PhD, Andre H Crepaldi, MD, Anna Marina Liberati, Philip Campbell, MBBS, FRACP, FRCPA, Tatiana Shelekhova, Sung-Soo Yoon, MD PhD, Genadi Iosava, Tomoaki Fujisaki, MD, Mamta Garg, MD, Christopher Chiu, PhD, Jianping Wang, Robin Carson, MD BA, Wendy Crist, BA, William Deraedt, Marie Nguyen, Ming Qi, Jesus F. San-Miguel, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): LBA-4.
https://doi.org/10.1182/blood.V130.Suppl_1.LBA-4.LBA-4
Published: 2017
Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance

Heinz Ludwig, MD, Wolfram Pönisch, MD, Alexander Egle, MD, Stefan Knop, MD, Martin Schreder, MD, Daniel Lechner, MD, Roman Hajek, Eberhard Gunsilius, Michael A. Fridrik, MD, Andreas Petzer, MD, Katja C. Weisel, Dietger Niederwieser, MD, Axel Hinke, PhD, Richard Greil, MD, Niklas Zojer, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1857.
https://doi.org/10.1182/blood.V130.Suppl_1.1857.1857
Published: 2017
Journal Articles

Age Related Distribution of Cytogenetic Abnormalities in Multiple Myeloma

Sonia Jaramillo, MD MSc, Miriam Kull, MD, Jan Kroenke, MD, Phyllis Schwarzwaelder, MD, Stefan Schoensteiner, MD, Stefan Knop, MD, Christian Straka, MD PhD, Hermann Einsele, Christian Langer, MD, Maria-Veronica Teleanu
Journal: Blood
Blood (2017) 130 (Supplement 1): 4381.
https://doi.org/10.1182/blood.V130.Suppl_1.4381.4381
Published: 2017
Journal Articles

Functional Geriatric Assessment (F-GA) in Multiple Myeloma Patients: Results from a Prospective Multicenter Study Group (DSMM) Trial and Changes from Baseline to Follow-up Assessment

Sophia Scheubeck, Sandra Maria Dold, M. Sc., Gabriele Ihorst, PhD, Alexander Zober, MD, Stefan J. Müller, Dipl.-Pharm., Christian Langer, MD, Wolfram Pönisch, Lars-Olof Mügge, MD, Stefan Knop, MD, Justus Duyster, MD, Martin Schumacher, PhD, Ralph M. Waesch, MD, Monika Engelhardt, MD
Journal: Blood
Blood (2016) 128 (22): 5627.
https://doi.org/10.1182/blood.V128.22.5627.5627
Published: 2016
Journal Articles

Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial

Heinz Ludwig, MD, Eberhard Gunsilius, MD, Michael Fridrik, MD, Richard Greil, Andreas Petzer, MD, Thomas Kühr, Univ. Doz. Dr., Stefan Knop, MD, Martin Schreder, MD, Elisabeth Rauch, Mag., Wolfram Poenisch, MD, Niklas Zojer, MD
Journal: Blood
Blood (2016) 128 (22): 3335.
https://doi.org/10.1182/blood.V128.22.3335.3335
Published: 2016
Journal Articles

Bortezomib Consolidation Following Autologous Transplant Equalizes the Outcome for Older Patients with Less Intensive Pretreatment Compared to Younger Patients with Newly Diagnosed Multiple Myeloma

Christian Straka, MD, Stefan Knop, MD, Martin Vogel, MD PhD, Jurgen Müller, Dipl. Stat., Martin Kropff, MD, Bernd Metzner, MD, Christian Langer, MD, Herbert Sayer, MD, Wolfram Jung, MD, Heinz Dürk, MD PhD, Hans-Juergen Salwender, MD, Hannes Wandt, MD, PhD, Florian Bassermann, MD, Martin Gramatzki, MD, Wolf Rösler, MD, Hans-Heinrich Wolf, MD, Wolfram Brugger, MD PhD, Monika Engelhardt, MD, Thomas Fischer, MD, Peter Liebisch, MD, Hermann Einsele, MD
Journal: Blood
Blood (2016) 128 (22): 516.
https://doi.org/10.1182/blood.V128.22.516.516
Published: 2016